TABLE 1.
Baseline Characteristics of Evaluated Patients
| N = 380 | |
|---|---|
| Age, median (range), years | 58 (22-82) |
| Gender, n | |
| Male | 210 |
| Female | 170 |
| Race, n (%) | |
| Caucasian | 225 (59) |
| African American | 116 (31) |
| Others | 39 (10) |
| Genotype, n (%) | |
| GT 1a | 264 (69) |
| GT 1b | 89 (24) |
| GT 1 or 1a/1b | 27 (7) |
| Metavir stage, n (%) | |
| F0 (stage 0) | 57 (15) |
| F1 (stage 1) | 64 (17) |
| F2 (stage 2) | 103 (27) |
| F3 (stage 3) | 86 (23) |
| Noncirrhotics, n % | 70 (18) |
| Baseline HCV RNA, mean (range), IU/mL | 1,630,000 million (493-5,960,000) |
| Gap between viral load testing and initiation of therapy, median (range), days | 100 (1-176) |
HCV = hepatitis C virus.